TY - JOUR
TI - Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
AU - Terpos, E.
AU - Gavriatopoulou, M.
AU - Ntanasis-Stathopoulos, I.
AU - Briasoulis, A.
AU - Gumeni, S.
AU - Malandrakis, P.
AU - Papanagnou, E.-D.
AU - Migkou, M.
AU - Kanellias, N.
AU - Kastritis, E.
AU - Trougakos, I.P.
AU - Dimopoulos, M.A.
JO - Blood advances
PY - 2022
VL - 139
TODO - 9
SP - 1409-1412
PB - Elsevier B.V.
SN - null
TODO - 10.1182/blood.2021014989
TODO - bnt 162b 2;  immunological antineoplastic agent;  immunomodulating agent;  lenalidomide;  neutralizing antibody;  proteasome inhibitor;  tozinameran, adult;  aged;  antibody production;  antibody response;  antibody titer;  cancer immunotherapy;  controlled study;  coronavirus disease 2019;  female;  human;  humoral immunity;  Letter;  major clinical study;  male;  multiple myeloma;  repeated drug dose;  Severe acute respiratory syndrome coronavirus 2;  vaccination
TODO - null
ER -